Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Archives of Cardiovascular Diseases|November 29, 2021
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA)Vincent Durlach, Dominique Bonnefont-Rousselot, Franck Boccara, et al.
Atherosclerosis. Supplements|August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapyCarlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
Atherosclerosis|March 22, 2020
Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registryIlse K Luirink, Barbara A Hutten, Susanne Greber-Platzer, et al.
Nature Genetics|May 6, 2003
Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaMarianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, et al.
Atherosclerosis|November 5, 2024
The singular French PCSK9-p.Ser127Arg gain-of-function variant: A significant player in cholesterol levels from a 775-year-old common ancestorYara Azar, Thomas E Ludwig, Hugo Le Bon, et al.
European Heart Journal|March 27, 2018
New prospects for PCSK9 inhibition?Ulf Landmesser, M John Chapman, Jane K Stock, et al.
European Heart Journal|October 19, 2017
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemiaUlf Landmesser, M John Chapman, Jane K Stock, et al.
Metabolites|March 24, 2022
Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial HypercholesterolemiaYoumna Ghaleb, Sandy Elbitar, Anne Philippi, et al.
Archives of Medical Science : AMS|April 11, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Archives of Cardiovascular Diseases|November 29, 2021
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA)Vincent Durlach, Dominique Bonnefont-Rousselot, Franck Boccara, et al.
Atherosclerosis. Supplements|August 29, 2015
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapyCarlos Aguiar, Eduardo Alegria, Riccardo C Bonadonna, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Carlos Aguiar, Eduardo Alegria, et al.
Atherosclerosis|March 22, 2020
Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registryIlse K Luirink, Barbara A Hutten, Susanne Greber-Platzer, et al.
Nature Genetics|May 6, 2003
Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaMarianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, et al.
Atherosclerosis|November 5, 2024
The singular French PCSK9-p.Ser127Arg gain-of-function variant: A significant player in cholesterol levels from a 775-year-old common ancestorYara Azar, Thomas E Ludwig, Hugo Le Bon, et al.
European Heart Journal|March 27, 2018
New prospects for PCSK9 inhibition?Ulf Landmesser, M John Chapman, Jane K Stock, et al.
European Heart Journal|October 19, 2017
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemiaUlf Landmesser, M John Chapman, Jane K Stock, et al.
Metabolites|March 24, 2022
Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial HypercholesterolemiaYoumna Ghaleb, Sandy Elbitar, Anne Philippi, et al.
Archives of Medical Science : AMS|April 11, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
Pageof 15